Drug
Odalasvir clinical trials
Also written ACH-3102.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2016 (8)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 8 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Janssen Research & Development, LLC (8) · Alexion Pharmaceuticals, Inc. (2) · Alios Biopharma Inc. (1) · Janssen Pharmaceutical K.K. (1)
Often tested with
Tested in the same studies.
Simeprevir (6) · Adafosbuvir (6) · Ribavirin (2) · Dabigatran (1) · Sovaprevir (1) · Drospirenone (1) · Ethinyl Estradiol (1) · Lansoprazole (1)
Studies
Open first, then newest update. How each study uses odalasvir is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02945020Written as Odalasvir (ODV)
- A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of OdalasvirCompletedPhase 1Janssen Research & Development, LLCNCT02961660Written as Odalasvir
- Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02824315Written as Odalasvir (ODV)
- Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV ParticipantsCompletedPhase 2Alexion Pharmaceuticals, Inc.NCT01849562Written as ACH-3102
- Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b ParticipantsCompletedPhase 1Alexion Pharmaceuticals, Inc.NCT01700179Written as ACH-0143102
- Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C InfectionCompletedPhase 2Janssen Research & Development, LLCNCT02765490Written as Odalasvir
- A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy VolunteersCompletedPhase 1Alios Biopharma Inc.NCT02512562Written as ACH-3102
- A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naiveCompletedPhase 2Janssen Pharmaceutical K.K.NCT02993250Written as Odalasvir (ODV)
- Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02821858Written as Odalasvir (ODV)
- Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)TerminatedPhase 1Janssen Research & Development, LLCNCT03059303Written as Odalasvir 25 mg
- A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02889367Written as Odalasvir 100 mg
- To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02885454Written as Odalasvir (ODV)
Given in every arm · 1 — odalasvir is usual care beside what is tested
Codes
What other systems call odalasvir · ClinicalTrials.gg INT001023
- MeSH (NLM) C000629482odalasvirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) OVR52K7BDWODALASVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q4650666odalasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174815OdalasvirOne source FDA
- DrugBank DB13041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629482 | odalasvir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | OVR52K7BDW | ODALASVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4650666 | odalasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174815 | Odalasvir | One source FDA |
| DrugBank | DB13041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.